Showing 871-880 of 1784 results for "".
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
https://reachmd.com/programs/cme/her2-breast-cancer-with-brain-metastases-rethinking-first-line-treatment-in-the-adc-era/56518/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC
https://reachmd.com/programs/cme/sequencing-systemic-and-local-therapy-in-her2-overexpressing-metastatic-nsclc/56520/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/Examine updated KDIGO 2025 IgAN guidelines and the new approach to managing proteinuria and slowing kidney function decline.The Ambulatory HFrEF Blind Spot: Proactively Reducing CV Mortality Risk Despite Optimized GDMT
https://reachmd.com/programs/cme/the-ambulatory-hfref-blind-spot-proactively-reducing-cv-mortality-risk-despite-optimized-gdmt/48810/Drs. Bauersachs, Butler & Lam discuss persistent residual risk in HFrEF, the use of sGC stimulators to reduce risk, and supporting evidence for this approach.Addressing CKM Mortality & Morbidity in Patients With CKD and T2D: The Role of Combined ns-MRA & SGLT2i Therapy
https://reachmd.com/programs/cme/addressing-ckm-mortality-morbidity-in-patients-with-ckd-and-t2d-the-role-of-combined-ns-mra-sglt2i-therapy/29907/Insights on CKD and T2D care: Experts explore CONFIDENCE trial results, combination therapy, and collaborative CKM care to reduce cardio-kidney risk.Beyond Fulvestrant: Oral SERDs Redefining ER Targeting
https://reachmd.com/programs/cme/beyond-fulvestrant-oral-serds-redefining-er-targeting/39800/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Spotlight on Latin America: Closing the Gap
https://reachmd.com/programs/cme/spotlight-on-latin-america-closing-the-gap/39809/Examine evolving global strategies for treating patients with HR+/HER2- mBC, integrating biomarker-driven therapy, clinical evidence, and toxicity management.Beyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/Examine how nonsteroidal MRAs inform risk-based treatment in HFpEF and HFmrEF, including stable patients with ongoing cardio-kidney-metabolic risk.EGFR-Mutated NSCLC With Brain Metastases: Navigating ADC Treatment Decisions
https://reachmd.com/programs/cme/egfr-mutated-nsclc-with-brain-metastases-navigating-adc-treatment-decisions/56521/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.Managing Brain Metastases Through Multidisciplinary Team Collaboration
https://reachmd.com/programs/cme/managing-brain-metastases-through-multidisciplinary-team-collaboration/56522/Apply clinical evidence and multidisciplinary strategies to select and sequence systemic and local therapies for brain metastases in breast and lung cancer.